达格列净在临床实践中的应用经验探索。
An exploration of the experience of dapagliflozin in clinical practice.
作者信息
Anitha Anuba Paulvarnan, Balasubramanian Swetha, Ramalingam Arun Gopal, Samuel Kennady Shini Rubina, Ganamurali Nila, Dhanasekaran Dhivya, Sabarathinam Sarvesh
机构信息
Department of Pharmacy Practice, SRM College of Pharmacy, SRM IST, Kattankulathur, Kancheepuram, Tamil Nadu, 603203, India.
Drug Testing Laboratory, Interdisciplinary Institute of Indian System of Medicine (IIISM), SRM Institute of Science & Technology, Kattankulathur, Tamil Nadu, 603203, India.
出版信息
Future Sci OA. 2022 Nov 1;8(8):FSO816. doi: 10.2144/fsoa-2022-0038. eCollection 2022 Sep.
Despite the availability of established treatments, heart failure (HF) is associated with a poor prognosis and suboptimal management, highlighting the need for new treatment and prevention options. It is suggested that sodium-glucose cotransporters 2 inhibitors can provide a beneficial therapeutic approach to significantly lower the disease burden associated with cardiovascular illness in both patients with and without Type 2 diabetes mellitus. This review focuses on the therapeutic aspects of dapagliflozin in clinical practice. Future studies may intend to confirm the significant clinical benefits of sodium-glucose cotransporter-2 inhibitors.
尽管已有成熟的治疗方法，但心力衰竭（HF）的预后较差且管理欠佳，这凸显了对新的治疗和预防方案的需求。有研究表明，钠-葡萄糖协同转运蛋白2抑制剂可以提供一种有益的治疗方法，显著降低2型糖尿病患者和非2型糖尿病患者心血管疾病相关的疾病负担。本综述聚焦于达格列净在临床实践中的治疗作用。未来的研究可能旨在证实钠-葡萄糖协同转运蛋白2抑制剂的显著临床益处。
Zotero 插件